Literature DB >> 15856329

Catastrophic antiphospholipid antibody syndrome.

Jyoti Sharma1, Srilekha Karthik, Subba Rao, Kishore Phadke, Julian Crasta, Isha Garg.   

Abstract

Antiphospholipid antibody syndrome (APS) is characterized by recurrent thrombosis with the presence of circulating antiphospholipid antibodies. A diagnosis of APS requires the presence of at least one clinical and one laboratory criteria (detection of aCL IgG or IgM antibodies or the presence of lupus anticoagulant on two or more consecutive occasions 6 weeks apart). A severe, rapidly progressive form characterized by clinical involvement of at least three different organ systems with histopathological evidence of small and large vessel occlusion is termed catastrophic antiphospholipid syndrome. Early recognition of APS is crucial since aggressive management can result in a favorable outcome. We present the case of a 12-year-old boy who presented with a devastating illness with multiple thrombotic episodes and rapidly progressive renal failure.

Entities:  

Mesh:

Year:  2005        PMID: 15856329     DOI: 10.1007/s00467-004-1734-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

Review 1.  Prognosis in antiphospholipid syndrome.

Authors:  M C Amigo
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 3.  Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.

Authors:  R A Asherson; R Cervera; J C Piette; J Font; J T Lie; A Burcoglu; K Lim; F J Muñoz-Rodríguez; R A Levy; F Boué; J Rossert; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1998-05       Impact factor: 1.889

4.  [Effective combination therapy of plasma exchange and subsequent cyclophosphamide pulses for catastrophic antiphospholipid antibody syndrome: a case report].

Authors:  T Miyamae; T Imagawa; S Ito; S Katakura; M Mori; M Ibe; T Mitsuda; Y Aihara; S Nakanishi; T Kohri; S Yokota
Journal:  Ryumachi       Date:  1999-06

5.  The intrarenal vascular lesions associated with primary antiphospholipid syndrome.

Authors:  D Nochy; E Daugas; D Droz; H Beaufils; J P Grünfeld; J C Piette; J Bariety; G Hill
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

Review 6.  Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.

Authors:  T Avcin; R Cimaz; P L Meroni
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 7.  Protean clinical presentation of antiphospholipid-protein antibodies (APA).

Authors:  D A Triplett
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

  7 in total
  5 in total

1.  Catastrophic antiphospholipid syndrome presented with sudden renal failure and history of long-lasting psychosis and hypertension in a 42 years old women.

Authors:  Saeed Mardani; Hamid Nasri
Journal:  J Nephropathol       Date:  2013-04-01

Review 2.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Catastrophic antiphospholipid antibody syndrome in a child with thrombotic microangiopathy.

Authors:  N Prasad; D Bhadauria; N Agarwal; A Gupta; P Gupta; M Jain; H Lal
Journal:  Indian J Nephrol       Date:  2012-07

5.  Catastrophic antiphospholipid syndrome in a 7-year-old girl.

Authors:  Jee Min Park; Jae Il Shin; Youn Ho Shin; Dong Soo Kim; Jae Seung Lee; Myung Joon Kim; Seung Koo Lee; Do Yun Lee
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 3.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.